ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript [Seeking Alpha]
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: Seeking Alpha
Company Participants Nicole Riley - Head of Investor Relations & Corporate Communications Ameet Mallik - CEO & Director Mohamed Zaki - Chief Medical Officer Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Yuxi Dong - Jefferies LLC, Research Division Leonid Timashev - RBC Capital Markets, Research Division Sudan Loganathan - Stephens Inc., Research Division Robert Burns - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics SA LOTIS-7 update. [Operator Instructions] This call is being recorded on Wednesday, December 3, 2025. I would now like to turn the conference over to Nicole Riley, Head of Investor Relations and Corporate Communications. Please go ahead. Nicole Riley Head of Investor Relations & Corporate Communications Thank you, operator. Today, we issued a pr
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics (NYSE:ADCT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma [Yahoo! FinanceYahoo! Finance
- ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell LymphomaPR Newswire
- ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial [Yahoo! Finance]Yahoo! Finance
ADCT
Earnings
- 11/10/25 - Beat
ADCT
Sec Filings
- 11/13/25 - Form SCHEDULE
- 11/10/25 - Form S-3
- 11/10/25 - Form 10-Q
- ADCT's page on the SEC website